<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958970</url>
  </required_header>
  <id_info>
    <org_study_id>745-201</org_study_id>
    <nct_id>NCT01958970</nct_id>
  </id_info>
  <brief_title>Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting</brief_title>
  <official_title>A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pinta Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pinta Biotherapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to assess the safety, pharmacokinetics and effectiveness of PINTA 745&#xD;
      or placebo in treating protein energy wasting (PEW) in patients receiving maintenance&#xD;
      hemodialysis (MHD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (participants will be assigned by chance to study treatments),&#xD;
      double-blind (participants and study personnel will not know the identity of the study&#xD;
      treatments), placebo (an inactive substance that is compared with a drug to test whether the&#xD;
      drug has a real effect in a clinical trial)-controlled study in patients who receive&#xD;
      maintenance hemodialysis. Three participants will receive PINTA 745 for every participant&#xD;
      that receives placebo. PINTA 745 or placebo will be taken intravenously once per week&#xD;
      following dialysis.&#xD;
&#xD;
      The study period will consist of screening, treatment for 12 weeks, and follow up for 8&#xD;
      weeks. Evaluations will be performed to assess the safety, pharmacokinetics (study of what&#xD;
      the body does to a drug), pharmacodynamics (study of what a drug does to the body) and&#xD;
      effectiveness in treating protein energy wasting (such as increasing muscle size and muscle&#xD;
      function) throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose and Percent Changes in Lean Body Mass (LBM)</measure>
    <time_frame>MTD will be assessed after the last patient in Cohort 1A and Cohort 2A complete 28 days on treatment. LBM will be assessed for comparing baseline to Week 12</time_frame>
    <description>To evaluate the safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and pharmacokinetics of PINTA 745 and to evaluate percentage change in LBM relative to baseline at 12 weeks, via dual-energy x-ray absorptiometry(DXA) scans, in the group receiving PINTA 745 at the MTD (or if no MTD is reached, at the recommended phase 2 dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Composition - Lean Body Mass (LBM), Appendicular Lean Mass (ALM) and Mid Upper Arm Muscle Circumference (MUAMC)</measure>
    <time_frame>Baseline through Week 20</time_frame>
    <description>To evaluate the change in LBM and ALM via CT and dual-energy x-ray absorptiometry (DXA) scans relative to baseline at 12, 16 and 20 weeks. To evaluate change relative to baseline in MUAMC at 5, 9, 16 and 20 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Function</measure>
    <time_frame>Baseline through Week 20</time_frame>
    <description>To evaluate change in physical function as measured by the Stair Climbing Power Test (SCPT) and the 6 Minute Walk Test (6MWT) relative to baseline at 5, 9, 12, 16 and 20 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Kidney Disease</condition>
  <condition>Protein Energy Wasting</condition>
  <arm_group>
    <arm_group_label>PINTA 745</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PINTA 745</intervention_name>
    <description>PINTA 745 will be administered once weekly by IV infusion.&#xD;
Cohort dose schedules:&#xD;
3mg/kg weekly for 12 weeks&#xD;
3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks&#xD;
6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks</description>
    <arm_group_label>PINTA 745</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered once weekly by IV infusion.&#xD;
Cohort dose schedules:&#xD;
3mg/kg weekly for 12 weeks&#xD;
3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks&#xD;
6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ESRD patient and on outpatient maintenance hemodialysis for ≥ 6 months&#xD;
&#xD;
          -  Adequate dialysis with Kt/V ≥ 1.2 on two occasions within 12 weeks of enrollment&#xD;
&#xD;
          -  Undergoing dialysis at least 3 times per week, on average&#xD;
&#xD;
          -  Serum albumin ≤ 3.8g/dL within 60 days of enrollment&#xD;
&#xD;
          -  Able and willing to provide Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of an indwelling central vascular catheter&#xD;
&#xD;
          -  Current medical condition that would interfere with ability to perform physical&#xD;
             function tests&#xD;
&#xD;
          -  Active infection requiring hospitalization or antibiotics within the past month&#xD;
&#xD;
          -  Major surgery within past 3 months, minor surgery within the past 4 months&#xD;
&#xD;
          -  Dialysis access revision/angioplasty/replacement within the past 2 weeks&#xD;
&#xD;
          -  History of renal transplant, whether or not functional, within 2 years (however, if&#xD;
             graft has been removed, patient will be considered eligible) or plans to undergo renal&#xD;
             transplantation within 6 months&#xD;
&#xD;
          -  History of neoplasia, except non-melanoma skin cancers, with a 30% probability of&#xD;
             recurrence within 12 months&#xD;
&#xD;
          -  Current treatment with appetite stimulants, anabolic steroids or growth hormone&#xD;
&#xD;
          -  Clinically significant heart disease&#xD;
&#xD;
          -  Difficulty swallowing food or liquid&#xD;
&#xD;
          -  If female, currently breast feeding&#xD;
&#xD;
          -  If female, pregnant&#xD;
&#xD;
          -  If female or male, unwilling to use a highly effective method of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Haqq, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pinta Biotherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Advancement Center, PLLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>October 7, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>ESRD</keyword>
  <keyword>Maintenance Hemodialysis</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Dialysis</keyword>
  <keyword>MHD</keyword>
  <keyword>Protein Energy Wasting</keyword>
  <keyword>PEW</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

